Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup.
Authors
Hendrik-Tobias Arkenau
Sarah Cannon Research, London, United Kingdom
Hendrik-Tobias Arkenau , Josep Tabernero , Marcia Cruz-Correa , Anastasia V. Zimina , Elena Poddubskaya , Fedor Vladimirovich Moiseenko , David R. Spigel , Lucjan S. Wyrwicz , Umut Disel , Roberto Pazo Cid , Antonio Cubillo Gracian , Inmaculada Alés Diaz , Lorenzo Fornaro , Ludovic Evesque , Yaling Xu , Tao Sheng , Silu Yang , Liyun Li , Markus H. Moehler , Rui-Hua Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03777657
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 330)
DOI
10.1200/JCO.2024.42.3_suppl.330
Abstract #
330
Poster Bd #
F10
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first‑line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
First Author: Rui-hua Xu
Poster
2020 Gastrointestinal Cancers Symposium
Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma.
First Author: Harry H. Yoon
Poster
2021 Gastrointestinal Cancers Symposium
Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.
First Author: Josep Tabernero
Poster
2019 ASCO Annual Meeting
A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).
First Author: Jian-Ming Xu